Redox proteomics gives insights into the role of oxidative stress in alkaptonuria

References

• Phornphutkul C, Introne WJ, Perry MB et al. Natural history of alkaptonuria. N. Engl. J. Med. 347(26), 2111–2121 (2002).
   PubMed Web of Science ®Google Scholar
• Fernandez-Canon JM, Granadino B, Beltran-Valero De Bernabe D et al. The molecular basis of alkaptonuria. Nat. Genet. 14(1), 19–24 (1996).
   PubMed Web of Science ®Google Scholar
• Zatkova A, De Bernabe DB, Polakova H et al. High frequency of alkaptonuria in Slovakia: evidence for the appearance of multiple mutations in HGO involving different mutational hot spots. Am. J. Hum. Genet. 67(5), 1333–1339 (2000).
   Google Scholar
• Goicoechea De Jorge E, Lorda I, Gallardo Me et al. Alkaptonuria in the Dominican Republic: identification of the founder AKU mutation and further evidence of mutation hot spots in the HGO gene. J. Med. Genet. 39(7), e40 (2002).
   Google Scholar
• Garrod AE. The incidence of alkaptonuria: a study in chemical individuality. 1902 [classical article]. Yale J. Biol. Med. 75(4), 221–231 (2002).
   Google Scholar
• La Du BN, Zannoni VG, Laster L, Seegmiller JE. The nature of the defect in tyrosine metabolism in alcaptonuria. J. Biol. Chem. 230(1), 251–260 (1958).
   PubMed Web of Science ®Google Scholar
• Laschi M, Tinti L, Braconi D et al. Homogentisate 1,2 dioxygenase is expressed in human osteoarticular cells: implications in alkaptonuria. J. Cell. Physiol. 227(9), 3254–3257 (2012).
   Google Scholar
• Laxon S, Ranganath L, Timmis O. Living with alkaptonuria. BMJ 343, d5155 (2011).
   Google Scholar
• Helliwell TR, Gallagher JA, Ranganath L. Alkaptonuria–a review of surgical and autopsy pathology. Histopathology 53(5), 503–512 (2008).
   PubMed Web of Science ®Google Scholar
• Pettit SJ, Fisher M, Gallagher JA, Ranganath LR. Cardiovascular manifestations of Alkaptonuria. J. Inherit. Metab. Dis. 34(6), 1177–1181 (2011).
   Google Scholar
• Wilke A, Steverding D. Ochronosis as an unusual cause of valvular defect: a case report. J. Med. Case Rep. 3, 9302 (2009).
   PubMedGoogle Scholar
• Erek E, Casselman FR, Vanermen H. Cardiac ochronosis: valvular heart disease with dark green discoloration of the leaflets. Tex. Heart Inst. J. 31(4), 445–447 (2004).
   Google Scholar
• Gaines JJ, Jr. The pathology of alkaptonuric ochronosis. Hum. Pathol. 20(1), 40–46 (1989).
   Google Scholar
• Stenn FF, Milgram JW, Lee SL, Weigand RJ, Veis A. Biochemical identification of homogentisic acid pigment in an ochronotic egyptian mummy. Science 197(4303), 566–568 (1977).
   Google Scholar
• Lee SL, Stenn FF. Characterization of mummy bone ochronotic pigment. JAMA 240(2), 136–138 (1978).
   Google Scholar
• Presto Elgstoen KB, Jellum E. Capillary electrophoresis for diagnosis of metabolic disease. Electrophoresis 18(10), 1857–1860 (1997).
   Google Scholar
• Yamaguchi S, Koda N, Yamamoto H. Analysis for homogentisic acid by NMR spectrometry, to aid diagnosis of alkaptonuria. Clin. Chem. 35(8), 1806–1807 (1989).
   Google Scholar
• Bory C, Boulieu R, Chantin C, Mathieu M. Diagnosis of alcaptonuria: rapid analysis of homogentisic acid by HPLC. Clin. Chim. Acta 189(1), 7–11 (1990).
   Google Scholar
• Bory C, Boulieu R, Chantin C, Mathieu M. Homogentisic acid determined in biological fluids by HPLC. Clin. Chem. 35(2), 321–322 (1989).
   Google Scholar
• Jellum E, Thoresen O, Horn L et al. Advances in the use of computerized gas chromatography-mass spectrometry and high-performance liquid chromatography with rapid scanning detection for clinical diagnosis. J. Chromatogr. 468, 43–53 (1989).
   PubMedGoogle Scholar
• Mizuno T, Abe N, Teshima H et al. Application of a gas chromatography mass spectrometry computer system for clinical diagnosis. Biomed. Mass Spectrom. 8(12), 593–597 (1981).
   Google Scholar
• Borman P, Bodur H, Ciliz D. Ochronotic arthropathy. Rheumatol. Int. 21(5), 205–209 (2002).
   Google Scholar
• Groseanu L, Marinescu R, Laptoiun D et al. A late and difficult diagnosis of ochronosis. J. Med. Life 3(4), 437–443 (2010).
   Google Scholar
• Laskar FH, Sargison KD. Ochronotic arthropathy. A review with four case reports. J. Bone Joint Surg. Br. 52(4), 653–666 (1970).
   Google Scholar
• Vinjamuri S, Ramesh CN, Jarvis J, Gallagher JA, Ranganath LL. Nuclear medicine techniques in the assessment of alkaptonuria. Nucl. Med. Commun. 32(10), 880–886 (2011).
   Google Scholar
• Jebaraj I, Chacko BR, Chiramel GK, Matthai T, Parameswaran A. A simplified staging system based on the radiological findings in different stages of ochronotic spondyloarthropathy. Indian J. Radiol. Imaging 23(1), 101–105 (2013).
   Google Scholar
• De Haas V, Carbasius Weber EC, De Klerk JB et al. The success of dietary protein restriction in alkaptonuria patients is age-dependent. J. Inherit. Metab. Dis. 21(8), 791–798 (1998).
   PubMed Web of Science ®Google Scholar
• Kamoun P, Coude M, Forest M, Montagutelli X, Guenet JL. Ascorbic acid and alkaptonuria. Eur. J. Pediatr. 151(2), 149 (1992).
   Google Scholar
• Martin JP Jr., Batkoff B. Homogentisic acid autoxidation and oxygen radical generation: implications for the etiology of alkaptonuric arthritis. Free Radic. Biol. Med. 3(4), 241–250 (1987).
   Google Scholar
• Braconi D, Laschi M, Taylor AM et al. Proteomic and redox-proteomic evaluation of homogentisic acid and ascorbic acid effects on human articular chondrocytes. J. Cell Biochem. 111(4), 922–932 (2010).
   Google Scholar
• Guidarelli A, Fiorani M, Cantoni O. Enhancing effects of intracellular ascorbic acid on peroxynitrite-induced U937 cell death are mediated by mitochondrial events resulting in enhanced sensitivity to peroxynitrite-dependent inhibition of complex III and formation of hydrogen peroxide. Biochem. J. 378(Pt 3), 959–966 (2004).
   Google Scholar
• Guidarelli A, De Sanctis R, Cellini B, Fiorani M, Dacha M, Cantoni O. Intracellular ascorbic acid enhances the DNA single-strand breakage and toxicity induced by peroxynitrite in U937 cells. Biochem. J. 356(Pt 2), 509–513 (2001).
   Google Scholar
• Tinti L, Spreafico A, Braconi D et al. Evaluation of antioxidant drugs for the treatment of ochronotic alkaptonuria in an in vitro human cell model. J. Cell Physiol. 225(1), 84–91 (2010).
   Google Scholar
• Braconi D, Laschi M, Amato L et al. Evaluation of anti-oxidant treatments in an in vitro model of alkaptonuric ochronosis. Rheumatology (Oxford) 49(10), 1975–1983 (2010).
   Google Scholar
• Spreafico A, Millucci L, Ghezzi L et al. Antioxidants inhibit SAA formation and pro-inflammatory cytokine release in a human cell model of alkaptonuria. Rheumatology (Oxford) 52(9), 1667–1673 (2013).
   Google Scholar
• Introne WJ, Perry MB, Troendle J et al. A 3-year randomized therapeutic trial of nitisinone in alkaptonuria. Mol. Genet. Metab. 103(4), 307–314 (2011).
   PubMed Web of Science ®Google Scholar
• Suwannarat P, O'Brien K, Perry MB et al. Use of nitisinone in patients with alkaptonuria. Metabolism 54(6), 719–728 (2005).
   PubMed Web of Science ®Google Scholar
• Preston AJ, Keenan CM, Sutherland H et al. Ochronotic osteoarthropathy in a mouse model of alkaptonuria, and its inhibition by nitisinone. Ann. Rheum. Dis. doi:10.1136/annrheumdis-2012-202878 (2013) (Epub ahead of print).
   Google Scholar
• Taylor AM, Preston AJ, Paulk NK et al. Ochronosis in a murine model of alkaptonuria is synonymous to that in the human condition. Osteoarthritis Cartilage 20(8), 880–886 (2012).
   PubMed Web of Science ®Google Scholar
• Cox TM. Alkaptonuria: leading to the treasure in exceptions. JIMD Rep. 5, 49–57 (2012).
   Google Scholar
• Janocha S, Wolz W, Srsen S et al. The human gene for alkaptonuria (AKU) maps to chromosome 3q. Genomics 19(1), 5–8 (1994).
   Google Scholar
• Gehrig A, Schmidt SR, Muller CR, Srsen S, Srsnova K, Kress W. Molecular defects in alkaptonuria. Cytogenet. Cell Genet. 76(1–2), 14–16 (1997).
   Google Scholar
• Beltran-Valero De Bernabe D, Granadino B, Chiarelli I et al. Mutation and polymorphism analysis of the human homogentisate 1, 2-dioxygenase gene in alkaptonuria patients. Am. J. Hum. Genet. 62(4), 776–784 (1998).
   PubMed Web of Science ®Google Scholar
• Higashino K, Liu W, Ohkawa T et al. A novel point mutation associated with alkaptonuria. Clin. Genet. 53(3), 228–229 (1998).
   Google Scholar
• Beltran-Valero De Bernabe D, Jimenez FJ, Aquaron R, Rodriguez De Cordoba S. Analysis of alkaptonuria (AKU) mutations and polymorphisms reveals that the CCC sequence motif is a mutational hot spot in the homogentisate 1,2 dioxygenase gene (HGO). Am. J. Hum. Genet. 64(5), 1316–1322 (1999).
   Google Scholar
• Felbor U, Mutsch Y, Grehn F, Muller CR, Kress W. Ocular ochronosis in alkaptonuria patients carrying mutations in the homogentisate 1,2-dioxygenase gene. Br. J. Ophthalmol. 83(6), 680–683 (1999).
   Google Scholar
• Zatkova A, Polakova H, Micutkova L et al. Novel mutations in the homogentisate-1,2-dioxygenase gene identified in Slovak patients with alkaptonuria. J. Med. Genet. 37(7), 539–542 (2000).
   Google Scholar
• Zatkova A. An update on molecular genetics of Alkaptonuria (AKU). J. Inherit. Metab. Dis. 34(6), 1127–1136 (2011).
   Web of Science ®Google Scholar
• Zatkova A, Sedlackova T, Radvansky J et al. Identification of 11 novel homogentisate 1,2 dioxygenase variants in alkaptonuria patients and establishment of a novel LOVD-based HGD mutation database. JIMD Rep. 4, 55–65 (2012).
   PubMedGoogle Scholar
• Rodriguez JM, Timm DE, Titus GP et al. Structural and functional analysis of mutations in alkaptonuria. Hum. Mol. Genet. 9(15), 2341–2350 (2000).
   Google Scholar
• Cox TF, Ranganath L. A quantitative assessment of alkaptonuria: testing the reliability of two disease severity scoring systems. J. Inherit. Metab. Dis. 34(6), 1153–1162 (2011).
   Google Scholar
• Ranganath LR, Cox TF. Natural history of alkaptonuria revisited: analyses based on scoring systems. J. Inherit. Metab. Dis. 34(6), 1141–1151 (2011).
   PubMed Web of Science ®Google Scholar
• Millucci L, Spreafico A, Tinti L et al. Alkaptonuria is a novel human secondary amyloidogenic disease. Biochim. Biophys. Acta 1822(11), 1682–1691 (2012).
   PubMed Web of Science ®Google Scholar
• Hegedus ZL, Nayak U. Homogentisic acid and structurally related compounds as intermediates in plasma soluble melanin formation and in tissue toxicities. Arch. Int. Physiol. Biochim. Biophys. 102(3), 175–181 (1994).
   PubMedGoogle Scholar
• Hegedus ZL. The probable involvement of soluble and deposited melanins, their intermediates and the reactive oxygen side-products in human diseases and aging. Toxicology 145(2–3), 85–101 (2000).
   PubMed Web of Science ®Google Scholar
• Rocha Jc, Martins Mj. Oxidative stress in phenylketonuria: future directions. J. Inherit. Metab. Dis. 35(3), 381–398 (2012).
   Google Scholar
• De Andrade RB, Gemelli T, Rojas DB, Funchal C, Dutra-Filho CS, Wannmacher CM. Tyrosine impairs enzymes of energy metabolism in cerebral cortex of rats. Mol. Cell Biochem. 364(1–2), 253–261 (2012).
   Google Scholar
• Sgaravatti AM, Magnusson AS, De Oliveira AS et al. Tyrosine administration decreases glutathione and stimulates lipid and protein oxidation in rat cerebral cortex. Metab. Brain Dis. 24(3), 415–425 (2009).
   Google Scholar
• Kabuyama Y, Kitamura T, Yamaki J, Homma MK, Kikuchi S, Homma Y. Involvement of thioredoxin reductase 1 in the regulation of redox balance and viability of rheumatoid synovial cells. Biochem. Biophys. Res. Commun. 367(2), 491–496 (2008).
   PubMed Web of Science ®Google Scholar
• Braconi D, Bernardini G, Bianchini C et al. Biochemical and proteomic characterization of alkaptonuric chondrocytes. J. Cell Physiol. 227(9), 3333–3343 (2012).
   Google Scholar
• Braconi D, Bianchini C, Bernardini G et al. Redox-proteomics of the effects of homogentisic acid in an in vitro human serum model of alkaptonuric ochronosis. J. Inherit. Metab. Dis. 34(6), 1163–1176 (2011).
   Google Scholar
• Tinti L, Spreafico A, Chellini F, Galeazzi M, Santucci A. A novel ex vivo organotypic culture model of alkaptonuria-ochronosis. Clin. Exp. Rheumatol. 29(4), 693–696 (2011).
   Google Scholar
• Tinti L, Taylor AM, Santucci A et al. Development of an in vitro model to investigate joint ochronosis in alkaptonuria. Rheumatology (Oxford) 50(2), 271–277 (2011).
   PubMed Web of Science ®Google Scholar
• Bay-Jensen AC, Wichuk S, Byrjalsen I et al. Circulating protein fragments of cartilage and connective tissue degradation are diagnostic and prognostic markers of rheumatoid arthritis and ankylosing spondylitis. PLoS ONE 8(1), e54504 (2013).
   PubMed Web of Science ®Google Scholar
• Gibson DS, Rooney ME, Finnegan S et al. Biomarkers in rheumatology, now and in the future. Rheumatology (Oxford) 51(3), 423–433 (2012).
   PubMed Web of Science ®Google Scholar
• Kentsis A. Challenges and opportunities for discovery of disease biomarkers using urine proteomics. Pediatr. Int. 53(1), 1–6 (2011).
   Google Scholar
• Karsdal MA, Nielsen MJ, Sand JM et al. Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure. Assay Drug. Dev. Technol. 11(2), 70–92 (2013).
   PubMed Web of Science ®Google Scholar
• Berlett BS, Stadtman ER. Protein oxidation in aging, disease, and oxidative stress. J. Biol. Chem. 272(33), 20313–20316 (1997).
   PubMed Web of Science ®Google Scholar
• Brandes N, Schmitt S, Jakob U. Thiol-based redox switches in eukaryotic proteins. Antioxid. Redox. Signal. 11(5), 997–1014 (2009).
   PubMed Web of Science ®Google Scholar
• Jones DP. Radical-free biology of oxidative stress. Am. J. Physiol. Cell Physiol. 295(4), C849–C868 (2008).
   PubMed Web of Science ®Google Scholar
• Schafer FQ, Buettner GR. Redox environment of the cell as viewed through the redox state of the glutathione disulfide/glutathione couple. Free Radic. Biol. Med. 30(11), 1191–1212 (2001).
   PubMed Web of Science ®Google Scholar
• Winterbourn CC, Hampton MB. Thiol chemistry and specificity in redox signaling. Free Radic. Biol. Med. 45(5), 549–561 (2008).
   PubMed Web of Science ®Google Scholar
• Held JM, Gibson BW. Regulatory control or oxidative damage? Proteomic approaches to interrogate the role of cysteine oxidation status in biological processes. Mol. Cell Proteomics 11(4), R111 013037 (2012).
   Google Scholar
• Fedorova M, Bollineni RC, Hoffmann R. Protein carbonylation as a major hallmark of oxidative damage: Update of analytical strategies. Mass Spectrom. Rev. doi:10.1002/mas.21381 (2013) (Epub ahead of print).
   Google Scholar
• Giustarini D, Dalle-Donne I, Lorenzini S et al. Protein thiolation index (PTI) as a biomarker of oxidative stress. Free Rad. Biol. Med. 53(4), 907–915 (2012).
   Google Scholar
• Angeles AP, Badger R, Gruber HE, Seegmiller JE. Chondrocyte growth inhibition induced by homogentisic acid and its partial prevention with ascorbic acid. J. Rheumatol. 16(4), 512–517 (1989).
   Google Scholar
• Ibold Y, Lubke C, Pelz S et al. Effect of different ascorbate supplementations on in vitro cartilage formation in porcine high-density pellet cultures. Tissue Cell 41(4), 249–256 (2009).
   Google Scholar
• Bernardini G, Braconi D, Spreafico A, Santucci A. Post-genomics of bone metabolic dysfunctions and neoplasias. Proteomics 12(4–5), 708–721 (2012).
   PubMed Web of Science ®Google Scholar
• Taylor AM, Wlodarski B, Prior IA et al. Ultrastructural examination of tissue in a patient with alkaptonuric arthropathy reveals a distinct pattern of binding of ochronotic pigment. Rheumatology (Oxford) 49(7), 1412–1414 (2010).
   Google Scholar
• Obici L, Merlini G. AA amyloidosis: basic knowledge, unmet needs and future treatments. Swiss Med. Wkly. 142, w13580 (2012).
   PubMed Web of Science ®Google Scholar
• Dyall SC. Amyloid-beta peptide, oxidative stress and inflammation in alzheimer's disease: potential neuroprotective effects of omega-3 polyunsaturated fatty acids. Int. J. Alzheimer's Dis. 21(5), 364–73 (2010).
   Google Scholar
• Kamalvand G, Ali-Khan Z. Immunolocalization of lipid peroxidation/advanced glycation end products in amyloid A amyloidosis. Free Radic. Biol. Med. 36(5), 657–664 (2004).
   Google Scholar
• Ando Y, Nyhlin N, Suhr O et al. Oxidative stress is found in amyloid deposits in systemic amyloidosis. Biochem. Biophys. Res. Commun. 232(2), 497–502 (1997).
   PubMed Web of Science ®Google Scholar
• Ando Y, Brannstrom T, Uchida K et al. Histochemical detection of 4-hydroxynonenal protein in Alzheimer amyloid. J. Neurol. Sci. 156(2), 172–176 (1998).
   Google Scholar
• Van Der Hilst JCH, Kluve-Beckerman B, Van Der Meer JWM, Simon A. Cathepsin D activity protects against development of type AA amyloid fibrils. Eur. J. Clin. Invest. 39(5), 412–416 (2009).
   Google Scholar
• Sohal RS, Allen RG. Oxidative stress as a causal factor in differentiation and aging: a unifying hypothesis. Exp. Gerontol. 25(6), 499–522 (1990).
   Google Scholar
• Sticozzi C, Pecorelli A, Lim Y et al. Modulation of skin oxidative stress and inflammatory markers by environmental stressors. Differences between young and old. J. Dermatol. Sci. 65(3), 226–228 (2012).
   Google Scholar
• Sohal RS, Orr WC. The redox stress hypothesis of aging. Free Radic. Biol. Med. 52(3), 539–555 (2012).
   Google Scholar
• Giustarini D, Dalle-Donne I, Lorenzini S, Milzani A, Rossi R. Age-related influence on thiol, disulfide, and protein-mixed disulfide levels in human plasma. J. Gerontol. A Biol. Sci. Med. Sci. 61(10), 1030–1038 (2006).
   PubMed Web of Science ®Google Scholar
• Cerioni L, Fiorani M, Azzolini C, Cantoni O. A moderate decline in U937 cell GSH levels triggers PI3 kinase/Akt-dependent Bad phosphorylation, thereby preventing an otherwise prompt apoptotic response. Pharmacol. Res. 65(3), 379–386 (2012).
   Google Scholar
• Valacchi G, Weber Su, Luu C, Cross Ce, Packer L. Ozone potentiates vitamin E depletion by ultraviolet radiation in the murine stratum corneum. FEBS Lett. 466(1), 165–168 (2000).
   Google Scholar
• Steinhubl SR. Why have antioxidants failed in clinical trials? Am. J. Cardiol. 101(10A), 14D–19D (2008).
   Web of Science ®Google Scholar
• Kaspar RL. Challenges in developing therapies for rare diseases including pachyonychia congenita. J. Investig. Dermatol. Symp. Proc. 10(1), 62–66 (2005).
   Google Scholar
• Burns KH, Chakravarti A. Massively parallel rare disease genetics. Genome Med. 3(5), 29 (2011).
   Google Scholar
• D'alessandro A, Rinalducci S, Zolla L. Redox proteomics and drug development. J. Proteomics 74(12), 2575–2595 (2011).
   PubMed Web of Science ®Google Scholar
• Abbott A. Rare-disease project has global ambitions. Nature 472(7341), 17 (2011).
   Google Scholar
• Mitsumoto A, Takeuchi A, Okawa K, Nakagawa Y. A subset of newly synthesized polypeptides in mitochondria from human endothelial cells exposed to hydroperoxide stress. Free Radic. Biol. Med. 32(1), 22–37 (2002).
   Google Scholar
• Mackness B, Mackness M. The antioxidant properties of high-density lipoproteins in atherosclerosis. Panminerva Med. 54(2), 83–90 (2012).
   PubMed Web of Science ®Google Scholar
• Teoh CL, Griffin MD, Howlett GJ. Apolipoproteins and amyloid fibril formation in atherosclerosis. Protein Cell 2(2), 116–127 (2011).
   Google Scholar
• Gursky O, Mei X, Atkinson D. The crystal structure of the C-terminal truncated apolipoprotein A-I sheds new light on amyloid formation by the N-terminal fragment. Biochemistry 51(1), 10–18 (2012).
   PubMed Web of Science ®Google Scholar
• Obici L, Franceschini G, Calabresi L et al. Structure, function and amyloidogenic propensity of apolipoprotein A-I. Amyloid 13(4), 191–205 (2006).
   PubMed Web of Science ®Google Scholar
• Mukhopadhyay CK, Fox PL. Ceruloplasmin copper induces oxidant damage by a redox process utilizing cell-derived superoxide as reductant. Biochemistry 37(40), 14222–14229 (1998).
   PubMed Web of Science ®Google Scholar
• Ghiso J, Matsubara E, Koudinov A et al. The cerebrospinal-fluid soluble form of Alzheimer's amyloid beta is complexed to SP-40,40 (apolipoprotein J), an inhibitor of the complement membrane-attack complex. Biochem. J. 293(Pt 1), 27–30 (1993).
   Google Scholar
• Yerbury JJ, Poon S, Meehan S et al. The extracellular chaperone clusterin influences amyloid formation and toxicity by interacting with prefibrillar structures. FASEB J. 21(10), 2312–2322 (2007).
   PubMed Web of Science ®Google Scholar
• Kumita JR, Poon S, Caddy GL et al. The extracellular chaperone clusterin potently inhibits human lysozyme amyloid formation by interacting with prefibrillar species. J. Mol. Biol. 369(1), 157–167 (2007).
   Google Scholar
• Chacko G, Ling Q, Hajjar KA. Induction of acute translational response genes by homocysteine. Elongation factors-1alpha, -beta, and -delta. J. Biol. Chem. 273(31), 19840–19846 (1998).
   Google Scholar
• Nakajima H, Amano W, Fujita A et al. The active site cysteine of the proapoptotic protein glyceraldehyde-3-phosphate dehydrogenase is essential in oxidative stress-induced aggregation and cell death. J. Biol. Chem. 282(36), 26562–26574 (2007).
   PubMed Web of Science ®Google Scholar
• Dastoor Z, Dreyer JL. Potential role of nuclear translocation of glyceraldehyde-3-phosphate dehydrogenase in apoptosis and oxidative stress. J. Cell Sci. 114(Pt 9), 1643–1653 (2001).
   Google Scholar
• Hara MR, Cascio MB, Sawa A. GAPDH as a sensor of NO stress. Biochim. Biophys. Acta 1762(5), 502–509 (2006).
   Google Scholar
• Asleh R, Marsh S, Shilkrut M et al. Genetically determined heterogeneity in hemoglobin scavenging and susceptibility to diabetic cardiovascular disease. Circ. Res. 92(11), 1193–1200 (2003).
   Google Scholar
• Turturici G, Sconzo G, Geraci F. Hsp70 and its molecular role in nervous system diseases. Biochem. Res. Int. 2011, 618127 (2011).
   Google Scholar
• Fuentes-Almagro CA, Prieto-Alamo MJ, Pueyo C, Jurado J. Identification of proteins containing redox-sensitive thiols after PRDX1, PRDX3 and GCLC silencing and/or glucose oxidase treatment in Hepa 1–6 cells. J. Proteomics 77, 262–279 (2012).
   Google Scholar
• Tolosano E, Altruda F. Hemopexin: structure, function, and regulation. DNA Cell Biol. 21(4), 297–306 (2002).
   PubMed Web of Science ®Google Scholar
• Lumb RA, Bulleid NJ. Is protein disulfideisomerase a redox-dependent molecular chaperone? EMBO J. 21(24), 6763–6770 (2002).
   PubMedGoogle Scholar
• Honjo Y, Ito H, Horibe T, Takahashi R, Kawakami K. Protein disulfide isomerase-immunopositive inclusions in patients with Alzheimer disease. Brain Res. 1349, 90–96 (2010).
   PubMed Web of Science ®Google Scholar
• Taira T, Saito Y, Niki T, Iguchi-Ariga SM, Takahashi K, Ariga H. DJ-1 has a role in antioxidative stress to prevent cell death. EMBO Rep. 5(2), 213–218 (2004).
   PubMed Web of Science ®Google Scholar
• Shendelman S, Jonason A, Martinat C, Leete T, Abeliovich A. DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation. PLoS Biol. 2(11), e362 (2004).
   PubMed Web of Science ®Google Scholar
• Sekito A, Koide-Yoshida S, Niki T, Taira T, Iguchi-Ariga SM, Ariga H. DJ-1 interacts with HIPK1 and affects H2O2-induced cell death. Free Radic. Res. 40(2), 155–165 (2006).
   PubMed Web of Science ®Google Scholar
• Clements CM, Mcnally RS, Conti BJ, Mak TW, Ting JP. DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2. Proc. Natl Acad. Sci. USA 103(41), 15091–15096 (2006).
   PubMed Web of Science ®Google Scholar
• Wang J, Pantopoulos K. Regulation of cellular iron metabolism. Biochem. J. 434(3), 365–381 (2011).
   PubMedGoogle Scholar
• Turell L, Radi R, Alvarez B. The thiol pool in human plasma: The central contribution of albumin to redox processes. Free Radic. Biol. Med. 65C, 244–253 (2013).
   Google Scholar
• Tsai YC, Lee YM, Lam KK et al. The role of heat shock protein 70 in the protective effect of YC-1 on beta-amyloid-induced toxicity in differentiated PC12 cells. PLoS ONE 8(7), e69320 (2013).
   Google Scholar
• Muller T, Concannon CG, Ward MW et al. Modulation of gene expression and cytoskeletal dynamics by the amyloid precursor protein intracellular domain (AICD). Mol. Biol. Cell 18(1), 201–210 (2007).
   Google Scholar